Press Releases
2024
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2023
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2022
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2021
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2020
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2019
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2018 & Prior
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Media
Therapeutic frontiers: the potential of RRx-001 and AdAPT-001
Molecule RRx-001 Receives Fast Track Designation From the FDA – EpicentRx
AdAPT-001 oncolytic adenovirus shows promising phase 1 cancer treatment results
2023 Molecule RRx-001 Receives Fast Track Designation From the FDA – EpicentRx
Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient
Profile EpicentRx, Inc
RRx-001: Jack of all trades, master of…many
EpicentRx Shares Deeper Look Into Phase 2 Data Regarding Oral Mucositis
The Case for RRx-001 as a Radiation Countermeasure
A pandemic waiting to happen: Acute radiation syndrome and the immediate need for nuclear countermeasures
Eyeing untapped niche, EpicentRx makes case for cancer toxicity prevention drug
PREVLAR: Phase 2a randomized trial to assess the safety and efficacy of RRx-001 in the attenuation of oral mucositis in patients receiving head and neck chemoradiotherapy
RRx-001 Plus Irinotecan Improves Efficacy vs Regorafenib in Colorectal Cancer
FightMND Supports ALS Research on Inflammasome Blocker RRx-001
EBOOK Drug Target Review Immuno-oncology ebook 2022
ARMED ONCOLYTIC VIRUSES – Instant Messaging Cancer With a TGF-Beta Trap Carrying Oncolytic Adenovirus
What Exactly Is Inflammation (and What Is It Not?)
Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot
Dr. Tony Reid, MD, PhD interview with Oncology Tube – REPLATINUM Phase III
The Dictatorship of Cancer: How to Topple it in Three – Not So Easy – Steps
What do dictators and the military have in common with tumors and stroma? The answer: symbiosis – a relationship in which two different types closely and intimately interact with each other to the benefit of at least one of the types. The famous phrase, “no man is an...
AdAPT-001 Mechanism of Action
AdAPT-001 doesn’t just create a cancer-targeted infection, it produces a proprietary TGFβ “trap”...
Conferences
American Chemical Society, Western Regional Meeting 2013
October 2013, Santa Clara, California
Oral Presentation: High resolution MS proves that the developmental cancer drug, RRx-001, alkylates the hemoglobin beta chain
3rd International Workshop on Nitric Oxide in Cancer Therapy 2013
May 2013, Kingston, Ontario
Abstract: RRx-001, a hypoxia activated, nitric oxide generating cytotoxic agent: Phase 1 study results
American Association for Cancer Research (AACR) Annual Meeting 2013
April 2013, Washington, D.C.
Abstract: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent
15th International Symposium on Anti-Angiogenic Therapy 2013
January 2013, La Jolla, California
Abstract: Antivascular activity of RRx-001 in SCCVII and U87 tumors
Abstract: RRx-001: A novel hypoxia activated nitric oxide generating vascular disrupting agent (VDA)
Abstract: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent
American Society of Hematology (ASH) 2012
December 2012, Atlanta Georgia
Abstract: Treatment with a novel dinitroazetidine, ABDNAZ, improves nitrite reductase activity of sickle red blood cells
American Association for Cancer Research (AACR) Annual Meeting 2012
March 2012, Chicago Illinois
Abstract: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors
American Society of Hematology (ASH) 2011
December 2011, San Diego, California
Abstract: NO or no NO, increased reduction of nitrite to nitric oxide by modified red blood cells
International Society for the Study of Xenobiotics (ISSX) 2011
April 2011, Atlanta, Georgia
Abstract: Disposition of 14C-RRx-001 in rats after a single intravenous administration and in blood from rats, dogs, monkeys, and humans
American Association for Cancer Research (AACR) Annual Meeting 2011
April 2011, Orlando, Florida
Abstract: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials’
The recent backdrop of the very polarizing US Presidential election serves as the central analogy for an EpicentRx-authored article about macrophages in the December edition of PharmaTimes. Read more here and cast your vote on this well-written article entitled “Outside the Box”:…